NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology
September 21 2020 - 1:00PM
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S.
Patent and Trademark Office will issue on September 22, 2020
U.S. Patent No. 10,780,269 titled “Apparatus and Method for
Relieving Pain Using Transcutaneous Electrical Nerve Stimulation."
The patent covers core Quell technology that regulates
electrical stimulation based on the device
orientation. No other wearable pain relief device has
position dependent stimulation control technology that allows the
device to automatically modulate treatment based on the user's body
position. This technology is used in Quell's overnight therapy
modes as well for other features.
"We are pleased to have received this latest patent, which
describes core Quell technology,” said Shai N. Gozani, M.D.,
Ph.D., President and Chief Executive Officer of NeuroMetrix.
“We are continually working to make Quell smarter and more
automated so that our customers can focus less on controlling their
device and more on enjoying their lives. This patent further
establishes Quell as the innovation leader in this area.
NeuroMetrix now has 15 issued U.S. utility patents covering
Quell® technology."
About Quell
Quell is a novel transcutaneous electrical nerve stimulator
(TENS) for the symptomatic relief and management of chronic pain
that is available over-the-counter. It is a wearable device that
can be used during the day while active and at night while
sleeping. Quell users can personalize and manage therapy discreetly
via the Quell app. Quell also offers health tracking metrics
relevant to chronic pain sufferers. Quell users can synchronize
their data with the Quell Health Cloud®, which provides customized
feedback and powers a large chronic pain outcomes database.
Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is a leading developer and manufacturer of
diagnostic and therapeutic neurostimulation-based medical devices
that are used throughout the world. The Company has three FDA
cleared commercial products. DPNCheck® is a point-of-care test
that is used to evaluate peripheral neuropathies. ADVANCE™ is a
point-of-care device that provides nerve conduction studies as an
aid in diagnosing and evaluating patients suspected of having focal
or systemic neuropathies. Quell® is a wearable, mobile app
enabled, neurostimulation device indicated for symptomatic relief
and management of chronic pain and is available over-the-counter.
The Company maintains an active, industry-leading R&D program.
For more information, visit NeuroMetrix.com.
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com Source:
NeuroMetrix, Inc.
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Sep 2023 to Sep 2024